Listed

BioNexus Gene Lab Corp: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 16, 2022 and accepted by EDGAR at May 16, 2022, 12:27 ET.

Share

Management's discussion and analysis

As filed, 19,150 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Description of Business

As used herein, unless the context otherwise indicates, references to the “Company,” “we,” “our,” “us,” “BioNexus” refer to BioNexus Gene Lab Corp., a Wyoming company (BGLC), and its wholly owned subsidiaries, Bionexus Gene Lab Sdn. Bhd. (“Bionexus Malaysia”), and Chemrex Corporation Sdn. Bhd. (“Chemrex”), both are Malaysian companies.

BGLC is an emerging molecular lab focused on the application of functional genomics to enable early detection of infectious diseases and cancers. On August 23, 2017, we acquired all of the outstanding capital stock of BioNexus Malaysia, which was incorporated in Malaysia on April 7, 2015. BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which we use in our business. Our non-invasive blood screening tests analyze changes in ribonucleic acid (or RNA) to detect Covid-19, Dengue, HIV, HPV and the risk potentiality of cancers diseases. This unique blood genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body currently.

The corporate and principal office address of the Company and BioNexus Malaysia is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. Another lab focuses on Covid-19 and Colon cancer screening is located at 4th floor, Lifecare Diagnostic Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 1221-26512 and our web-site is www.bionexusgenelab.com (http://www.bionexusgenelab.com).

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate office and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and web-site is www.chemrex.com.my (http://www.chemrex.com.my).

Forward-Looking Statements

Certain statements made in this quarterly report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) in regard to the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the registrant to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this quarterly report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the registrant or any other person that the objectives and plans of the registrant will be achieved.

Substantial risks exist with respect to an investment in the Company. These risks include but are not limited to, those factors discussed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2021. More broadly, these factors include, but are not limited to:

  • We have limited operating history and limited business growth;
  • The efficacy of our blood screening process;
  • We may face product liability claims and we have no insurance to cover such claims; and
  • There are risks associated with our business operations in Malaysia, including enforcing judgements against our operating subsidiary and management.

The results of operations of our subsidiary, BioNexus-Malaysia, with respect to its RNA screening process have been adversely impacted by the onset of the Covid-19 pandemic, which commenced in late December 2019 in Malaysia. We believe that most people have been and will continue to be reluctant to visit hospitals and clinics during the Covid-19 pandemic for fear of transmission from other patients or medical staff. Since our RNA screening is administered at a diagnostic center, our business has been adversely affected as a result. Furthermore, on March 18, 2020, the Malaysian government first imposed its Movement Control Order (MCO) which lasted through June 9, 2020 to control the spread of COVID-19. The MCO restricted movement of all people except for those who were working for essential services. The MCOs were enhanced and relaxed at different phases in 2020 and 2021, including the Enhanced Movement Control Order (EMCO), Conditional Movement Control Order (CMCO) and Recovery Movement Control Order (RMCO). This Enhanced Movement Control Orders were implemented whenever there was a surge of Covid-19 cases. During these EMCOs, only companies classified under essential service were allowed to operate. This EMCO ended on July 16, 2021 and the government allowed more companies and factories to operate with strict Standard Operation Procedures. However, as discussed below, during fiscal 2021, BioNexus-Malaysia implemented the sale of its Covid19 qPCR test procedure through the Malaysian government. Our Covid testing generates substantially lower per ticket charges at $30-38 per test compared with $975 per customer for our RNA testing. Our Covid tests also generate lower margins than our RNA tests.

The results of operations for Chremrex were adversely impacted during the fiscal years of 2020 and 2021 due to the MCO’s and Covid-19.

23

Table of Contents

Recent Developments. As previously reported, we submitted to the Malaysian Ministry of Health (HHS) our Reverse Transcription Polymerase Chain Reaction (RT PCR) Covid-19 screening for approval, which occurred in June 2020. On April 30, 2021, BioNexus entered into an Agreement with HHS to outsource our Covid19 qPCR test for its public hospitals and clinics within Malaysia. The use of our testing protocol began on May 6, 2021. We expect that our testing protocol would be continued to be used by the HHS’ public hospitals and clinics through August 2021, when the pandemic curve is expected to flatten in 2022.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective period and year:

March 31, 2022 December 31, 2021
Period ended March 31, 2022 /Year-ended December 31, 2021 US$1: MYR exchange rate 4.2060 4.1650
January 1, 2022 to March 31, 2022 January 1, 2021 to March 31, 2021
3 months average US$1: MYR exchange rate 4.1938 4.0678

24

Table of Contents

Results of Operations

Three Months Ended March 31, 2022 Compared with the Three Months Ended March 31, 2021.

The following table sets forth key selected financial data for the three months ended March 31, 2022 and 2021.

Consolidated

Three months ended March 31, 2022 2021
REVENUE $3,028,945 $3,449,159
COST OF REVENUE (2,695,406) (2,866,594)
GROSS PROFIT 333,539 582,565
OTHER INCOME 46,394 62,388
OPERATING EXPENSES
General and administrative (345,242) (302,851)
PROFIT FROM OPERATIONS 34,691 342,102
FINANCE COSTS (3,326) (3,358)
PROFIT BEFORE TAX 31,365 338,744
Tax expense (14,299) -
NET PROFIT $17,066 $338,744
Other comprehensive income:
Foreign currency loss (68,776) (208,468)
COMPREHENSIVE (LOSS)/ INCOME $(51,710) $130,276

Segmented Information

BioNexus Malaysia Three months ended March 31, 2022 Chemrex BioNexus Malaysia Three months ended March 31, 2021 Chemrex
REVENUE $24,269 $3,004,676 $97,363 $3,351,796
COST OF REVENUE (30,832) (2,664,574) (67,707) (2,798,887)
GROSS (LOSS)/PROFIT (6,563) 340,102 29,656 552,909
OTHER INCOME 2,076 44,306 763 61,625
OPERATING EXPENSES
General and administrative (21,248) (297,769) (22,511) (233,152)
FINANCE COSTS (799) (2,527) (1,207) (2,151)
PROFIT/(LOSS) BEFORE TAX (26,534) 84,112 6,701 379,231
Tax expense - (14,299) - -
NET (LOSS)/PROFIT $(26,534) $69,813 $6,701 $379,231

25

Table of Contents

Revenue. For the quarterly period ended March 31, 2022, we had total revenue of $3,028,945 as compared to total revenue of $3,449,159 for the same period in 2021, had decreased to $420,214 from prior quarter, a decrease of approximately 12.2%.

Chemrex contributed $3,004,676 (99.2%) of the total revenue for the current quarterly period as compared to $3,351,796 (97.2%) of the total revenue for the same quarter last year. Chemrex’s revenues had decreased by $347,120 from prior quarter, a decrease of 10.4%. The revenue decreased in 2022 was due Singapore Power Project has completed in the year 2021 and currently, there is no new project in this quarter.

BioNexus-Malaysia contributed $24,269 (0.8%) of the total revenue for the current quarter as compared to revenue of $97,363 (2.8%) of the total revenue from the same quarter last year. BioNexus’s revenue had decreased by $73,094 from prior quarter, a decrease of 75.1%. The revenue decreased in 2022 was due to the outsource contract for Covid19 PCR test from Ministry of Health (HHS) has ended since last year December 2021, currently, Covid19 PCR test was referred by Singapore Airline for its passengers and through online marketing.

Cost of Revenue. For the quarterly period ended March 31, 2022, we incurred $2,695,406 in cost of revenues, as compared to $2,866,594 for the same quarter in 2021, a decrease of $171,888 approximately 6%. It is due to the same reasons stated above.

Chemrex had incurred $2,664,574 (98.9%) of the total cost of revenue during the current quarter as compared to the same period last year wherein Chemrex had incurred $2,798,887 (97.6%) of the total in cost of revenue. The decreased of $134,313, approximately 4.8% in Chemrex’s cost of revenues for the current period was due to the same reasons stated above.

BioNexus had incurred $30,832 (1.1%) of the total cost of revenues during the current quarter as compared to $67,707 (2.4%) for the same period in 2021. The decreased of $36,875, approximately 54.5% in cost of revenues for the current period. It was due to the same reasons stated above.

Gross Profit. For the quarterly period ended March 31, 2022, we had total gross profit of $333,539 as compared to gross profit of $582,565 for the same period in 2021, a decrease by $249,026, approximately 42.7% from the prior period.

Chemrex contributed $340,102 (102%) of the total gross profit for the current quarterly period as compared to $552,909 (94.9%) of the total gross profit for the same quarter last year. The gross profit decreased by $212,807, approximately 38.5% for Chemrex in current quarter was due to its decreased revenues for the current period and reasons as stated above.

BioNexus-Malaysia had gross loss of $6,563 of the total gross profit of $333,539 for the current quarter as compared to $29,656 (5.1%) of the total gross profit from the same quarter last year. The gross profit decreased by 122% was due to its decreased revenues for the current period as according to reasons stated above.

Other Income. For the quarterly period ended March 31, 2022, we had $46,394 as compared to $62,388 for the same quarter in 2021, a decrease by $15,994, approximately 25.6%. Chemrex contributed $44,306 (95.5%) of other income for the current quarterly period as compared to $61,625 (98.8%) of the other income for the same quarter last year. Chemrex’s other income decreased by $17,319, approximately 28.1% was due to loss on currency exchange.

BioNexus Malaysia had $2,076 for period ended March 31, 2022 as compared to $763 for the same period in 2021, an increase of $1,313, approximately 172.1% and it was due to last year bank interest from the excess fund generated by Covid-19 contract.

Operating Expenses. For the quarterly period ended March 31, 2022, we had a total operating expense of $345,242 as compared to total operating expenses of $302,851 for the same quarter in 2021, an increase by $42,391, approximately 14%. Operating expenses consists of general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, professional fees and marketing and travel expenses.

Chemrex had incurred $297,769 (86.2%) of the total operating expenses for the current quarter as compared to $233,152 (77%) of the total operating expenses for the same quarter last year. The increase of $64,617, approximately 27.7% for the current period in operating expenses was due to the increased commission payout, loss on fair value of investment and loss on realised forex.

BioNexus-Malaysia had incurred $21,248 (6.2%) of the total operating expenses for the current quarter as compared to $22,511 (7.4%) of the total operating expenses for the same quarter last year. The slight decrease of $1,263, approximately 5.6% in operating costs of the current quarter was due to less traveling expenses during movement control in view of the Covid-19 pandemic.

BGLC, the holding company had incurred $26,225 (7.6%) of total operating expenses for the current quarter as compared to $47,188 (15.6%) of the total operating expenses for the same quarter last year. The decreased of $20,963, approximately 44.4% in operating costs of the current quarter was due to the expenses incurred on a Life Science Virtual Investor Forum organized by OTC Market Group and the consolidated fiscal and the quarter financials for the merger of BGLC and Chemrex, both happened in 2020.

Profit/Loss from Operations. We had a profit from operations of $34,691 quarterly period ended March 31, 2022 as compared to $342,102 for the same period in 2021, a decrease of $307,411, approximately 89.9% for the reasons discussed above.

Income tax expense. For the three-month period ended March 31, 2022, we had $14,299 income tax which is an estimated expense from Chemrex and for Bionexus no tax provided as compared to $0 for the same quarter last year.

Foreign currency exchange gain/(loss). We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the US Dollar. Therefore, any change in the relevant exchange rate would require us to recognize a transaction gain or loss on revaluation. For the three-month period ended March 31, 2022, we experienced a foreign currency loss of $68,776 as compared with a foreign currency loss of $208,468 for the same period in 2021.

26

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2022, we had working capital of $4,616,388 compared with working capital of $4,821,100 as of December 31, 2021. The decrease in working capital as of March 31, 2022 from December 31, 2021 was due principally to the decrease in cash used in our operations.

Our primary uses of cash have been for operations. The main sources of cash have been from operational revenues and the private placement of our common stock. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:

  • Addition of administrative and marketing personnel as the business grows,
  • Development of a Company website,
  • Increases in advertising and marketing in order to attempt to generate more revenues, and
  • The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows provided by (used in) / generated from operating, investing, and financing activities for the three months ended March 31, 2022 and 2021:

Three months ended March 31, 2022 2021
Net cash (used in)/generated from Operating Activities $(37,839) $115,428
Net cash used in investing activities (197,133) (295,826)
Net cash used in generated from financing activities - (8,550)
Foreign currency translation adjustment (44,625) (124,085)
Net Change in Cash and Cash Equivalents $(279,597) $(313,033)

Operating Activities

During the three months ended March 31, 2022, the Company incurred a net profit of $17,066 which, after adjusting for amortization, depreciation, dividend income, fair value loss on share investment, an increase in inventories and a substantial reduction in trade receivables, deposits, trade payables, advance payment from customer, deferred revenue, operating lease liabilities, resulted in net cash of $37,839 being used in operating activities during the period. By comparison, during the three months ended March 31, 2021, the Company had a net profit of $338,744 after adjusting for amortization, depreciation, dividend income, fair value gain on share investments, a decrease in inventories, a reduce in receivables and deposits, a substantial reduction in trade payables, operating lease liabilities, resulted in net cash of $115,428 being generated from operating activities during the period.

Investing Activities

During the three months ended March 31, 2022, the Company had net cash of $197,133 used in investment activities from acquisition of share investment of $172,172 and purchase of lab equipment. During the three months ended March 31, 2021, the Company had net cash from acquisition of share investment of $296,025 and purchase of plant and equipment, resulting in net cash generated from financing activities of $295,826

Financing Activities

During the three months ended March 31, 2022, Company has no repayment of a finance lease resulting in net cash used in financing activities. By comparison, during the three months ended March 31, 2021, we had financing activities of $8,550 for the repayment of a finance lease.

27

Table of Contents

Market risk

As filed, 147 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Controls and procedures

As filed, 6,190 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this quarterly report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of March 31, 2022. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were capable in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

i) Pertain to the maintenance of records that is in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;

ii) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and the board of directors; and

iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management conducted an assessment of the effectiveness of our internal control over financial reporting as of March 31, 2022, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting. A material weakness is a control deficiency, or a combination of deficiencies in internal control over financial reporting that creates a reasonable possibility that a material misstatement in annual or interim financial statements will not be prevented or detected on a timely basis. Since the assessment of the effectiveness of our internal control over financial reporting did identify a material weakness, management considers its internal control over financial reporting required improvement.

Management has concluded that our internal control over financial reporting had the material deficiencies. A majority of independent members and a majority of outside directors on our Board of Directors is only happened in May 2022, meanwhile there is an inadequacy in the monitoring of required internal controls and procedures.

While these control deficiencies did not result in any audit adjustments to our 2022 or 2021 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties. Accordingly, we have determined that this control deficiency constitutes a material weakness.

To the extent reasonably possible, given our limited resources, upon consummation of a merger with a private operating company, the Company has separated the responsibilities of principal executive officer and principal financial officer, and relying on two or more individuals. We are expanding our current board of directors to include additional individuals willing to perform directorial functions. Since the recited remedial actions and we will hire or engage additional personnel, this material weakness may be overcome in the near term. Until such remedial actions can be realized, we will continue to rely on the advice of outside professionals and consultants.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

During the quarter ended March 31, 2022, there has been no change in internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

28

Table of Contents

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$3.0mus-gaap:Revenues
Cost of revenue3 months2022-01-01 to 2022-03-31$2.7mus-gaap:CostOfRevenue
Gross profit3 months2022-01-01 to 2022-03-31$333.5kus-gaap:GrossProfit
Operating income3 months2022-01-01 to 2022-03-31$34.7kus-gaap:OperatingIncomeLoss
Income tax3 months2022-01-01 to 2022-03-31$14.3kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-01-01 to 2022-03-31$17.1kus-gaap:NetIncomeLoss
Operating cash flow3 months2022-01-01 to 2022-03-31−$37.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$32.2kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$1.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$6.6mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$9.2mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$2.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$2.0mus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$7.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001477932-22-003360. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.